Actively Recruiting
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-11-20
60
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.
CONDITIONS
Official Title
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For neoadjuvant therapy: T2-T4aN0M0 bladder cancer patients
- For adjuvant therapy: Patients with postoperative pathological stage T3-T4 and/or positive lymph node metastasis
- Age 18 years or older
You will not qualify if you...
- Patients unable to tolerate radical surgery as evaluated by researchers
- Previous systemic chemotherapy or immunotherapy
- Active autoimmune diseases requiring systemic treatment or other diseases needing long-term use of steroids or immunosuppressants
- Major surgery or major trauma within 28 days before joining the study
- Vaccination with a live vaccine within 28 days before joining the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
Research Team
X
Xiao Yang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here